168 related articles for article (PubMed ID: 16250929)
1. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
[TBL] [Abstract][Full Text] [Related]
2. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Edelman MJ
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
[TBL] [Abstract][Full Text] [Related]
3. Sequencing bortezomib with chemotherapy and targeted agents.
Adjei AA
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
[TBL] [Abstract][Full Text] [Related]
4. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
5. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
6. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
7. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
[TBL] [Abstract][Full Text] [Related]
8. Activity of bortezomib in advanced non-small-cell lung cancer.
Reddy KG
Clin Lung Cancer; 2004 Nov; 6(3):141-2. PubMed ID: 15555213
[No Abstract] [Full Text] [Related]
9. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Soria JC
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
[No Abstract] [Full Text] [Related]
10. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
11. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
13. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Mack PC; Davies AM; Lara PN; Gumerlock PH; Gandara DR
Lung Cancer; 2003 Aug; 41 Suppl 1():S89-96. PubMed ID: 12867067
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
15. Preclinical data with bortezomib in lung cancer.
Schenkein DP
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S49-55. PubMed ID: 16250927
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
[TBL] [Abstract][Full Text] [Related]
17. Incorporating bortezomib into the treatment of lung cancer.
Davies AM; Lara PN; Mack PC; Gandara DR
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
[TBL] [Abstract][Full Text] [Related]
18. The potential role of proteasome inhibitors in the treatment of lung cancer.
Bunn PA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
[TBL] [Abstract][Full Text] [Related]
19. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
